- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.08. | Ascentage Pharma Group International GAAP EPS of -$0.24, revenue of $32.6M | 1 | Seeking Alpha | ||
| 21.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates | 147 | GlobeNewswire (Europe) | Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced commercial... ► Artikel lesen | |
| 21.08. | ASCENTAGE-B (06855): ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 2 | HKEx | ||
| 18.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 18.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA | 119 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery... ► Artikel lesen | |
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| 18.08. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - GLOBAL REGISTRATIONAL PHASE III STUDY OF LISAFTOCLAX FOR FIRST-LINE TREATMENT OF HR-MDS CLEARED BY FDA AND ... | 1 | HKEx | ||
| 08.08. | ASCENTAGE-B (06855): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| 07.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 | 1 | GlobeNewswire (USA) | ||
| 01.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Participate in Evercore China Biotech Summit | 1 | GlobeNewswire (USA) | ||
| 25.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 25.07. | ASCENTAGE-B (06855): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 25.07. | ASCENTAGE-B (06855): CLOSING OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| 17.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement | 1 | GlobeNewswire (USA) | ||
| 15.07. | ASCENTAGE-B (06855): PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 14.07. | Ascentage Pharma Prices Top-Up Placement At HKD68.60 Per Share | 1 | RTTNews | ||
| 14.07. | Ascentage Pharma announces $192.3 million share placement | 1 | Investing.com | ||
| 14.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Pricing of Top-Up Placement | 1 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
72 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,700 | -1,60 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 22,400 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| ARCELLX | 72,71 | +0,93 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| NUVALENT | 78,50 | -0,29 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| BIONTECH | 86,45 | +0,06 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
| 89BIO | 8,520 | -1,27 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,605 | 0,00 % | Is Summit Therapeutics a Buy, Sell, or Hold Now? | ||
| EVOTEC | 5,846 | +0,62 % | Evotec Prognose gekappt: Rettet der "Priority Reset"? | Evotec hat im Juli seine Umsatzprognose überraschend gesenkt und damit Anleger verunsichert. Trotz Kostensenkungen und der geplanten Veräußerung der Produktionsanlage in Toulouse bleibt das Vertrauen... ► Artikel lesen | |
| TANGO THERAPEUTICS | 6,360 | -6,74 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| TOURMALINE BIO | 47,590 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,830 | 0,00 % | Amylyx Pharmaceuticals, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 38,590 | 0,00 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| AVIDITY BIOSCIENCES | 46,360 | 0,00 % | Avidity Biosciences kündigt Aktienemission im Wert von 500 Millionen US-Dollar an | ||
| TREVI THERAPEUTICS | 9,610 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,750 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 33,600 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.